A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia

Open For Enrollment

Please contact us for more information or to learn if you are eligible to participate.

To evaluate the effect of tildacerfont in reducing A4 in subjects with CAH over 12 weeks

5323 S. McColl Rd., Edinburg, TX 78539

(956) 362-2390